CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $3.32M, lower than 95% of all stocks globally
- PositionCurrent ratio is 23.14×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
381.48MUSDvs all stocks (USD)
Revenue (TTM)
3.32MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-34.12%vs all stocks
Market Capitalization
381.48MUSDvs all stocks (USD)
Enterprise Value
88.02MUSDvs all stocks (USD)
Forward P/E
-2.43xvs Biotechnology peers
Price to Book (MRQ)
1.25xvs Biotechnology peers
Enterprise to Revenue
26.50xvs Biotechnology peers
Enterprise to EBITDA
-0.5120xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-4218.09%vs Biotechnology peers
Return on Assets (TTM)
-27.76%vs Biotechnology peers
Return on Equity (TTM)
-41.83%vs Biotechnology peers
Revenue (TTM)
3.32MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0610USDUpdated Jul 19, 2026Quarterly Revenue Growth
82.70%vs Biotechnology peers
Gross Profit (TTM)
3.32MUSDvs all stocks (USD)
EBITDA (TTM)
-171.77MUSDvs all stocks (USD)
Net Income (TTM)
-156.76MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
82.69%vs Biotechnology peers
Operating Cash Flow (TTM)
-139.96MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-90.31MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.85MUSDFY2025 · Dec 31, 2025Operating Income
-160.36MUSDvs all stocks (USD)
Pre-tax Income
-143.44MUSDFY2025 · Dec 31, 2025Net Income
-143.44MUSDFY2025 · Dec 31, 2025EBIT
-160.36MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-160.17MUSDFY2025 · Dec 31, 2025Research & Development
136.81MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
26.41MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.93MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.66USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.66USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.85MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.85MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-143.44MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-134.26MUSDFY2025 · Dec 31, 2025Free Cash Flow
-134.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
101.77MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-143.44MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
188.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.33MUSDFY2025 · Dec 31, 2025Other Non-cash Items
561.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-55.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.28MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-565.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-165.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-385.88MUSDFY2025 · Dec 31, 2025Sale of Investments
292.56MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-93.48MUSDFY2025 · Dec 31, 2025Other Financing Charges
-34.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-34.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
54.42MSharesUpdated Jul 19, 2026Float Shares
40.53MSharesUpdated Jul 19, 2026Shares Short
4.11MSharesUpdated Jul 19, 2026Short Ratio
5.65daysvs all stocks
Short % of Shares Outstanding
11.63%vs all stocks
% Held by Insiders
14.88%vs all stocks
% Held by Institutions
88.32%vs all stocks
Total Cash (MRQ)
294.58MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.41USDUpdated Jul 19, 2026Total Debt (MRQ)
1.11MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0037xvs Biotechnology peers
Current Ratio (MRQ)
23.14xvs Biotechnology peers
Book Value per Share (MRQ)
5.59USDUpdated Jul 19, 2026Total Assets
353.77MUSDvs all stocks (USD)
Total Current Assets
351.80MUSDFY2025 · Dec 31, 2025Total Liabilities
14.00MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.98MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
549.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
101.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
239.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
668.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.73MUSDFY2025 · Dec 31, 2025Short-term Debt
720.00KUSDFY2025 · Dec 31, 2025Long-term Debt
549.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
54.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-334.22MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
339.77MUSDvs all stocks (USD)
52-Week Low
5.85USDUpdated Jul 19, 202652-Week High
33.68USDUpdated Jul 19, 202652-Week Change
-34.12%vs all stocks
50-Day MA
7.53USDUpdated Jul 19, 2026200-Day MA
16.59USDUpdated Jul 19, 2026Avg 10-Day Volume
449.29KSharesUpdated Jul 19, 2026Avg 30-Day Volume
625.92KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.90USDUpdated Jul 19, 2026Other Income / Expense
-15.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 23.14×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 23.14Industry median: 5.64Industry P95: 23.02Peers compared: 261
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $3.32M, lower than 95% of all stocks globallySignificant
Revenue (USD): 3,322,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Larimar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Sealsq Corp
3 interpretationsLow-Leverage Liquidity ConfigurationDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Draganfly Inc.
3 interpretationsLow-Leverage Liquidity ConfigurationDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Richtech Robotics Inc.
3 interpretationsLow-Leverage Liquidity ConfigurationDecline With Range Expansion And DrawdownHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC